Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Hormonal Therapies Offer Effective Solutions For Many Adult Women With Acne
Although acne traditionally has been considered a disease of teenagers, it is also extremely common in adult women. Studies show that acne affects more than 50 percent of women between the ages of 20-29 and more than 25 percent of women between the ages of 40-49 (1). In fact, after age 20, women are far more likely to report having acne than men. While there is no cure for acne, dermatologists are finding that hormonal therapies can help some women fight bothersome acne that occurs in adulthood.
generic viagra online
Biotronics3D Collaborates With The Institute Of Cancer Research To Develop Oncology Software
Biotronics3D has worked with The Institute of Cancer Research (ICR) to develop and launch new software to significantly improve the accuracy of MRI scan analysis. Called 3D Net Perfusion, the system extracts data from images of tumours and transforms it into usable information.
News of the day
In Joint Statement, Industry Groups Reiterate Commitment To Reduce Health Spending Growth
The six industry groups that pledged to reduce health care spending growth by $2 trillion over 10 years on Friday issued a statement reaffirming their commitment to work toward the goal, Roll Call reports (Murray, Roll Call, 5/15). The industry groups in a letter sent to President Obama on May 10 wrote, "We will do our part to achieve your administration"s goal of decreasing by 1.5 percentage points the annual health care spending growth rate. ... This represents more than a 20% reduction in the projected rate of growth." The letter -- which was signed by the American Medical Association, the American Hospital Association, Pharmaceutical Research and Manufacturers of America, the Advanced Medical Technology Association, America"s Health Insurance Plans and the Service Employees International Union -- did not elaborate on what specific measures the groups would take to achieve such reductions (Kaiser Daily Health Policy Report, 5/12). Obama in a May 11 public announcement of the groups" pledge said the coalition"s goal was to cut the growth rate by 1.5 percentage points "each year," which would total $2 trillion over 10 years (Norman, CQ HealthBeat, 5/15).However, industry leaders who attended the meeting with Obama said that they did not promise specific year-by-year savings, but instead agreed to a more incremental approach (Kaiser Daily Health Policy Report, 5/15). Richard Umbdenstock, president of AHA, said, "There"s been a lot of misunderstanding that has caused a lot of consternation among our members." AHA sent its members a bulletin stating that "the groups did not support reducing the rate of health spending by 1.5 percentage points annually," and that the pledge was to eventually reduce the growth rate by 1.5 percentage points (CQ HealthBeat, 5/15).In response to media reports that said they were backing away from their pledge, the groups on Friday in a joint statement reiterated their vow. They wrote, "Our organizations are currently engaged in an intensive process to develop proposals to reduce the rate of increase in future health care costs" (Young, The Hill, 5/15). The statement also said, "We are committed to working together to bend the health care cost curve" and "to doing our part to make reform sustainable and to make the system more affordable and effective for patients and purchasers" (Budoff Brown, Politico, 5/18). It continued that "to be successful, we must take action in public-private partnership. We look forward to offering cost-savings recommendations in the weeks ahead." The Obama administration has requested specifics on the coalition"s cost-cutting plans by June 1. White House Office of Management and Budget Director Peter Orszag on Friday in a blog post wrote that it is "understandable" that the groups need to "ramp up" to the 1.5 percentage point reduction in spending. According to Orszag, "The groups have committed to significant reductions in the growth rate, thereby recognizing that substantial efficiencies can be captured in the health system. Some ramp-up time also does not materially affect the long-term impact from reducing the growth rate, on either national health expenditures or the federal budget" (CQ HealthBeat, 5/15). Orszag"s blog posting is available online.
Mental Health

PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound

PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by PharmaMar"s internal research program. The first patient enrolled in the trial has already started treatment with the compound. PM1183 is a new synthetic alkaloid which binds to the minor groove of DNA, generates DNA double strand breaks and caused cell cycle perturbation that finally results in a specific type of cell death calles apoptosis. Results from preclinical studies indicate a pattern of activity of PM1183 different from that of conventional alkylating agents. In preclinical studies PM1183 demonstrated strong in vitro and in vivo antitumoural activity in a wide variety of tumour cell lines and human transplantable xenografted tumours. PM11883 also demonstrated a manageable and reversible preclinical toxicology profile. As a single agent, PM1183 significantly reduced tumor proliferation in vivo, with the strongest effect observed on the xenografts of the breast cancer cell line MX1. PM1183 was also evaluated for in vivo activity using M5076 sarcoma model that spontaneously metastasizes in the liver of the C57Bl/6 female tumor bearing mice. The compound statistically reduced the number of liver metastasis compared to placebo-treated animal. In vitro studies show cell lines with mutant p53 or lacking P53 are more sensitive with PM1183. Further studies are on going in human ovarian cancer and human sarcoma xenografts. PharmaMar"s clinical portfolio currently includes five new, first-in-class compounds: Yondelis®, Aplidin®, Zalypsis®, Irvalec® and PM1183. The PharmaMar patent portfolio is composed of over 1,800 files and it has a continous flow of new compound into the clinic (1 new compound every 24 months). About PM1183 PM1183 is a new synthetic alkaloid compound developed by PharmaMar"s internal research program. It binds to the minor groove of DNA, generates DNA double strand brakes and caused cell cycle perturpation mainly consisting in a delayed progression of S phase and cycle arrest in G2M. Results from preclinical studies indicate a pattern of activity of PM1183 different from that of conventionaol alkylating agents. PharmaMar PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar"s first product, Yondelis®, received marketing authorisation from the European Commission for the treatment of advanced or metastatic soft tissue sarcoma in September 2007. In 2008 a registration dossier was submitted to the European Medicines Agency (EMEA) and Food and Drug Administration (FDA, USA) for Yondelis® when administered in combination with DOXIL®/Caelyx™ (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer. It is also in phase II clinical trials for prostate, breast, and lung cancers. Three other PharmaMar compounds, Aplidin®, Irvalec®, and Zalypsis® are in various stages of clinical development. PharmaMar


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009